ATYR

#4085
aTyr Pharma, Inc. Common Stock
0.8409 USD
+3.76%
Сектор:
Базовая: USD
Валюта прибыли: USD
Дневной диапазон
0.8409
0.8409
Годовой диапазон
0.7200
1.1100
Дневное изменение
+3.76%
Месячное изменение
-1.07%
6-месячное изменение
-13.31%
Годовое изменение
-13.31%
Предыдущее закрытие
0.8104
Открыть
0.8409
Bid
Ask
Минимум
0.8409
High
0.8409
Объем
25
Открыть полный график

Financials

Обзор Отчетность Статистика
Квартал Год
  • Market Capitalization 82.4513 M
  • Employee 58
  • Founded 2005
  • CEO N/A
  • Website www.atyrpharma.com
  • Headquarter Delaware, United States
  • FIGI BBG001J2P692
  • Industry Technology
Общий доход
Чистая прибыль
Базовая прибыль на акцию
Общий долг
Свободный денежный поток
Денежные средства и эквиваленты
Коэффициент цена/прибыль
-0.98
Коэффициент цена/денежный поток
383.25

aTyr Pharma Inc

aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases. The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients. The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.